Study | Treatment | Dose and schedule | Patient numbera (total treated) | Analysis |
---|---|---|---|---|
CheckMate 009 (NCT01358721), phase I dose escalation | Nivolumab | 0.3, 2, and 10.0 mg/kg, Q3W | N = 89 (91) | Training dataset |
CheckMate 025 (NCT01668784), phase III | Nivolumab | 3.0 mg/kg, Q2W | N = 391 (406) | Training dataset |
Everolimus | 10.0 mg as a daily dose | N = 297 (397) | Test dataset | |
CheckMate 010 (NCT01354431), phase II dose ranging | Nivolumab | 0.3, 2, and 10.0 mg/kg, Q3W | N = 156 (167) | Test dataset |